IHC Markers Explained: HER2, ER, PR, Ki-67 Guide

”

Immunohistochemistry (IHC) markers have revolutionized cancer treatment. These tests on your biopsy sample reveal crucial information about your cancer's biology, helping doctors personalize your treatment for the best possible outcome.

Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to detect specific proteins (markers) in tissue samples. These markers provide critical information about:

• What type of cancer you have
• How aggressive the cancer might be
• What treatments are likely to work
• Your prognosis (outlook)

How it works:

1. Your biopsy tissue is treated with special antibodies
2. These antibodies bind to specific proteins in the cells
3. A stain makes these proteins visible under a microscope
4. The pathologist scores the results

Why IHC matters:

• Personalized medicine - treatment tailored to YOUR cancer
• Predicts which treatments will work
• Helps determine prognosis
• Guides treatment decisions

ER (Estrogen Receptor)

What it is:

• A protein that responds to the hormone estrogen
• Found on some cancer cells
• When estrogen binds to these receptors, it fuels cancer growth

Testing:

• Reported as a percentage (0-100%)
• Also reported as positive or negative
• Usually, >1% staining is considered positive

What positive means:

• Your cancer is fueled by estrogen
• Good news: You have more treatment options
• Hormone therapy can block estrogen
• Generally better prognosis

Treatment implications if ER+:

• Hormone therapy (tamoxifen, aromatase inhibitors)
• Ovarian suppression (in premenopausal women)
• May continue for 5-10 years
• Very effective treatment option

What negative means:

• Your cancer doesn't respond to estrogen
• Hormone therapies won't work
• Different treatment approaches needed

”

Quick summary: ER positive cancers have receptors for estrogen. Blocking estrogen (with medication) can effectively treat these cancers. ER is positive in about 70-80% of breast cancers.

PR (Progesterone Receptor)

What it is:

• A protein that responds to the hormone progesterone
• Similar to ER but responds to a different hormone
• Often tested alongside ER

Testing:

• Reported as a percentage (0-100%)
• Usually, >1% staining is considered positive
• Often correlated with ER status

What positive means:

• Your cancer responds to progesterone
• Usually positive when ER is positive
• Indicates more differentiated (less aggressive) cancer
• Good prognostic sign

Treatment implications:

• Similar to ER positive cancers
• Hormone therapy can be effective
• May have even better prognosis than ER+/PR- cancers

What negative means:

• Doesn't respond to progesterone
• Still may be ER positive (and still benefit from hormone therapy)
• ER+/PR- cancers may be more aggressive

”

Quick summary: PR status usually follows ER status. ER+/PR+ cancers have the best prognosis. ER+/PR- cancers are still treated with hormone therapy but may be more aggressive.

HER2 (Human Epidermal Growth Factor Receptor 2)

What it is:

• A protein that promotes cell growth
• Found on the surface of some cancer cells
• When present in excess, makes cancer grow faster

Testing:

• IHC testing first (scored 0, 1+, 2+, 3+)
• If IHC is 2+, FISH testing is done for confirmation
• FISH measures actual gene amplification

IHC scoring:

What positive (HER2+) means:

• Your cancer has too much HER2 protein
• Cancer tends to grow faster
• Used to have worse prognosis
• Good news: Targeted therapies now available!

Treatment implications if HER2+:

• Targeted therapy (trastuzumab/Herceptin)
• Other HER2-targeted drugs (pertuzumab, T-DM1, etc.)
• Very effective treatment revolution
• Dramatically improved outcomes

What negative (HER2-) means:

• No excess HER2 protein
• HER2-targeted therapies won't work
• Different treatment approach needed
• More common than HER2+

”

Quick summary: About 15-20% of breast cancers are HER2 positive. While HER2+ cancers are more aggressive, targeted therapies like Herceptin have dramatically improved outcomes for these patients.

Ki-67

What it is:

• A protein marker of cell proliferation (growth)
• Indicates how fast cells are dividing
• Higher Ki-67 = faster-growing cancer

Testing:

• Reported as a percentage (0-100%)
• No standard cutoff, but general guidelines exist
• Lower is generally better

Interpretation:

What high Ki-67 means:

• Cancer is growing more rapidly
• May be more aggressive
• May influence chemotherapy decisions
• May indicate need for more aggressive treatment

What low Ki-67 means:

• Slower-growing cancer
• Less aggressive behavior
• Better prognosis generally
• May be able to avoid chemotherapy in some cases

”

Important note: Ki-67 testing lacks standardization. Different labs may have different cutoffs. Always discuss the specific meaning with your doctor.

Double Positive (ER+ and/or PR+, HER2+)

Characteristics:

• About 10% of breast cancers
• Fueled by hormones AND HER2
• Can be treated with both hormone therapy and HER2-targeted therapy
• Good treatment options available

Triple Positive (ER+, PR+, HER2+)

Characteristics:

• All three markers positive
• Multiple treatment options
• Hormone therapy + HER2-targeted therapy
• Generally good prognosis with modern treatments

Hormone Positive, HER2 Negative (ER+ and/or PR+, HER2-)

Characteristics:

• Most common subtype (about 60-70% of breast cancers)
• Hormone-fueled, not HER2-driven
• Treated with hormone therapy
• Generally good prognosis
• May avoid chemotherapy in some cases

Triple Negative (ER-, PR-, HER2-)

Characteristics:

• About 10-15% of breast cancers
• No hormone receptors, no HER2
• More aggressive behavior
• Fewer targeted treatment options
• Historically worse prognosis
• Chemotherapy is main treatment
• More common in younger women and BRCA mutation carriers
• Newer treatments emerging (immunotherapy, PARP inhibitors)

Treatment challenges:

• No hormone therapy
• No HER2-targeted therapy
• Relies heavily on chemotherapy
• More likely to recur in first few years
• BUT: Many women do very well with treatment

”

Remember: "Triple negative" sounds scary, but many women with triple-negative breast cancer do very well with treatment. New therapies are continually being developed.

PD-L1

What it is:

• A protein that helps cancer evade the immune system
• Target for immunotherapy

What positive means:

• May respond to immunotherapy
• Used in several cancer types
• May have additional treatment options

ESR1 Mutations

What it is:

• Mutations in the estrogen receptor gene
• Can cause resistance to hormone therapy

Implications:

• May indicate need for different hormone therapy
• May develop during treatment
• Can be tested for in metastatic setting

BRCA1/2 Status

What it is:

• Gene mutations (germline or somatic)
• Increase cancer risk
• Can affect treatment

Implications:

• PARP inhibitors may be effective
• May indicate need for genetic counseling
• Affects treatment choices

MMR (Mismatch Repair) Status

What it is:

• Indicates DNA repair capability
• dMMR (deficient) or pMMR (proficient)

What dMMR means:

• May respond to immunotherapy
• May indicate Lynch syndrome
• Affects prognosis and treatment

Breast Cancer Treatment by IHC Status

When is Chemotherapy Recommended?

IHC markers help determine who needs chemotherapy:

Low risk (may avoid chemo):

• ER+, HER2-, low Ki-67
• Small tumors
• No lymph node involvement
• Used with genomic assays (Oncotype DX, MammaPrint)

Intermediate risk:

• Consider genomic testing
• Discuss risks and benefits
• Individual decision

High risk (chemo likely recommended):

• Triple negative
• HER2+ with large tumors or node involvement
• High Ki-67
• Large tumors or lymph node involvement

Sample Report

ESTROGEN RECEPTOR (ER):
Strong nuclear staining in 95% of tumor cells
INTERPRETATION: POSITIVE

PROGESTERONE RECEPTOR (PR):
Moderate nuclear staining in 80% of tumor cells
INTERPRETATION: POSITIVE

HER2 (c-erbB-2):
Strong complete membrane staining in 90% of tumor cells
INTERPRETATION: POSITIVE (3+)

Ki-67:
Nuclear staining in 25% of tumor cells
INTERPRETATION: ELEVATED

What this means:

• Triple positive breast cancer
• Excellent treatment options available
• Will receive hormone therapy + HER2-targeted therapy
• May or may not need chemo depending on other factors

How IHC Testing is Done

The process:

1. Biopsy tissue is processed and embedded in paraffin
2. Thin sections are cut and placed on slides
3. Slides are treated with specific antibodies
4. Staining makes the proteins visible
5. Pathologist examines and scores the results
6. Report is generated

Turnaround time:

• Usually 3-7 days after biopsy
• May take longer if special tests needed
• Your doctor will discuss results at follow-up

Quality Considerations

Testing accuracy:

• IHC testing is generally very accurate
• Accredited labs follow strict protocols
• Pathology review ensures quality
• Repeat testing may be done if results unclear

If results are unclear:

• Additional testing may be done
• Different lab may test the sample
• Second opinion may be recommended

About Your Results

1. What are my ER, PR, and HER2 results?
2. What does Ki-67 show and what does it mean?
3. Do I need any additional tests?
4. How do these results affect my treatment options?
5. What treatments do you recommend based on these results?

About Treatment

6. Will I need chemotherapy?
7. Will hormone therapy help me?
8. Is HER2-targeted therapy appropriate for me?
9. How long will treatment last?
10. What are the side effects of recommended treatments?

About Prognosis

11. What is my prognosis with these results?
12. How do these results affect my outlook?
13. What factors affect my prognosis beyond IHC markers?

"My report says 'equivocal' for HER2 - what does that mean?"

Equivocal (2+) means:

• Borderline result
• Not clearly positive or negative
• Needs additional testing (FISH)
• FISH gives a more definitive answer
• Don't worry until FISH results are back

"What if my results change over time?"

This can happen:

• ER/PR status can sometimes change
• HER2 status rarely changes
• Ki-67 may change
• Repeat biopsy may be done in metastatic setting
• Treatment may change based on new results

"How accurate are these tests?"

Accuracy:

• ER/PR testing: >95% accurate
• HER2 testing: very accurate with proper protocols
• Ki-67: less standardized but still useful
• False positives/negatives are rare but possible
• Quality lab processes ensure accuracy

"Do I need to be tested again?"

When retesting may be done:

• If original sample was inadequate
• If results are unclear
• In metastatic setting (to guide new treatment)
• If there's a discrepancy

Insurance Coverage

• Most insurance covers IHC testing
• Considered standard of care
• Usually included in pathology costs
• Check with your insurance if concerned

Special Testing

• Some tests may have additional costs
• Genomic assays (Oncotype DX, etc.) may not always be covered
• Financial assistance may be available
• Discuss costs with your healthcare team

IHC markers provide crucial information that guides your cancer treatment. Understanding these markers empowers you to participate in treatment decisions and understand your prognosis.

Key takeaways:

• ER/PR positive: Hormone therapy can be very effective
• HER2 positive: Targeted therapies available (good news!)
• Ki-67: Indicates how fast cancer is growing
• Combinations matter: Your complete profile guides treatment
• Treatment is personalized: YOUR cancer gets tailored treatment

Most importantly: IHC testing has revolutionized cancer care, enabling truly personalized treatment. Work closely with your healthcare team to understand your results and make informed decisions about your care.

Learn more:

• American Cancer Society: cancer.org
• Breastcancer.org: breastcancer.org
• American Society of Clinical Oncology: asco.org
• National Comprehensive Cancer Network: nccn.org

Find support:

• American Cancer Society Helpline: 1-800-227-2345
• Cancer Support Community: cancersupportcommunity.org
• Breastcancer.org Discussion Forums

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations. Your specific situation may vary.

Sources:

• American Cancer Society. "Understanding Your Pathology Report: Breast Cancer." 2024.
• College of American Pathologists. "HER2 Testing in Breast Cancer." 2024.
• National Comprehensive Cancer Network. "Breast Cancer Clinical Practice Guidelines." 2024.
• Breastcancer.org. "Hormone Receptor Status and HER2 Status." 2024.
• American Society of Clinical Oncology. "HER2 Testing Guidelines." 2024.
• Breastcancer.org. "Hormone Receptor Status and HER2 Status." 2024.